GRTS_2021_logoupdate_color.jpg
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
March 05, 2024 16:05 ET | Gritstone bio
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC)...
GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Workforce Reduction 
February 29, 2024 16:05 ET | Gritstone bio
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
GRTS_2021_logoupdate_color.jpg
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
February 21, 2024 07:00 ET | Gritstone bio
EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
February 12, 2024 07:00 ET | Gritstone bio
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 08, 2024 16:30 ET | Gritstone bio
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
GRTS_2021_logoupdate_color.jpg
Gritstone bio to Participate in Upcoming Investor Conference
January 17, 2024 07:00 ET | Gritstone bio
EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024 16:30 ET | Gritstone bio
EMERYVILLE, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2023 16:30 ET | Gritstone bio
EMERYVILLE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
GRTS_2021_logoupdate_color.jpg
Gritstone bio to Participate in Upcoming Investor Conferences
November 20, 2023 07:00 ET | Gritstone bio
EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
GRTS_2021_logoupdate_color.jpg
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 08, 2023 16:05 ET | Gritstone bio
-- BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b...